Monopar Therapeutics

Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing a treatment for Wilson disease and new radiopharmaceuticals for oncology. The company's Wilson disease product candidate is ALXN1840, an investigational once-daily, oral medicine in late-stage development. ALXN1840 (tiomolybdate choline) is designed to treat Wilson disease, a rare genetic condition affecting approximately 1 in 30,000 live births in the U.S., where the body accumulates toxic copper levels. There are an estimated 10,000 Wilson disease patients in the U.S., with about 5,000 currently diagnosed and treated. ALXN1840 has received Orphan Drug Designation in the U.S. and the EU, and Fast Track designation from the FDA. Monopar also has radiopharmaceutical programs targeting advanced cancers that express urokinase plasminogen activator receptor (uPAR). These include MNPR-101-Zr, which is in Phase 1 for imaging advanced cancers, and MNPR-101-Lu, which is in Phase 1a, and MNPR-101-Ac, which is in late preclinical-stage, both for the treatment of advanced cancers. The company builds its drug development pipeline through internal efforts and by licensing late preclinical- and clinical-stage therapeutics.